NEW YORK CITY, NY / ACCESS Newswire / August 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inspire Medical Systems, Inc. ("Inspire" or "the Company") (NYSE:INSP). Investors who purchased Inspire securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/INSP.
Investigation Details
On August 4, 2025, Inspire issued a press release announcing its second quarter financial results and updating its 2025 outlook. Among other items, Inspire reduced its full-year revenue outlook and diluted net income per share to $900 million – $910 million and $0.40 – $0.50, respectively, compared to prior guidance of $940 million – $955 million and $2.20 – $2.30. Inspire attributed the reductions to the slower-than-expected progress of the commercial launch of its next generation Inspire V neurostimulation system. On this news, Inspire’s stock price fell $42.04 per share, or 32.35%, to close at $87.91 per share on August 5, 2025.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Inspire securities, you can assist this investigation by visiting the firm’s site: bgandg.com/INSP. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original press release on ACCESS Newswire
COMTEX_467857819/2457/2025-08-07T11:01:20